Charles River Laboratories (NYSE: CRL) stock surged 12.64% in pre-market trading on Wednesday following a series of significant announcements that have boosted investor confidence. The company has reached a cooperation agreement with activist investor Elliott Investment Management, resulting in major governance updates and the initiation of a strategic review.

As part of the agreement, Charles River Laboratories will appoint four new directors to its board, including Elliott's Global Head of Engagement Steven Barg and three other independent directors with expertise in the pharmaceutical industry. The company also announced the launch of a comprehensive strategic review aimed at enhancing long-term stockholder value, which could potentially lead to improved business efficiency and other strategic initiatives.

Adding to the positive sentiment, Charles River Laboratories reported strong first-quarter 2025 financial results. The company's adjusted earnings per share came in at $2.34, significantly beating the analyst consensus estimate of $2.08. Revenue for the quarter reached $984.2 million, surpassing the expected $941.97 million. This robust performance, coupled with the strategic changes, has rekindled investor optimism in the contract research organization.